Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IBIO-600 · 1 trial · 1 indication
Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.
| Arm | Type | Description |
|---|---|---|
| IBIO-600 (Cohort 1) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 2) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 3) | EXPERIMENTAL | - |
| IBIO-600 (Cohort 4) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| IBIO-600 | DRUG | IBIO-600 Subcutaneous injection |
| Placebo | DRUG | Matching placebo; subcutaneous injection |
Inclusion Criteria: * Aged 18 to 65 years of age * In good general health, with no significant medical history * BMI between ≥ 27.0 and ≤ 34.90 kg/m2 * History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening. * Willingness to refrain ...
IBIO-600 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in adults who are overweight or obese.
IBIO-600 targets myostatin, a protein that regulates muscle growth. By targeting myostatin, the drug may influence muscle mass and metabolism, which could be relevant for weight management. However, the exact mechanism of action in treating overweight and obesity is still under investigation in clinical trials.
IBIO-600 is being developed by iBio, Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol IBIO. The company is conducting clinical trials to evaluate the safety and efficacy of this drug candidate for overweight and obesity.
IBIO-600 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies such as the FDA. The ongoing Phase 1 trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose in overweight or obese adults.
IBIO-600 is being evaluated in a Phase 1 clinical trial registered as NCT07487376. This study is recruiting participants in Australia and aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of IBIO-600 in overweight or obese adults. The trial is randomized, double-blind, and placebo-controlled, with an enrollment target of 32 participants.
No alternative names for IBIO-600 have been identified. It is a distinct investigational drug candidate developed by iBio, Inc. for the treatment of overweight and obesity. As it is still in early clinical development, it is not yet known by any other brand or generic name.